

Aaron C Logan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2959732/publications.pdf>

Version: 2024-02-01

66
papers

2,839
citations

236833

25
h-index

182361

51
g-index

67
all docs

67
docs citations

67
times ranked

4138
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. <i>British Journal of Haematology</i> , 2022, 197, 63-70. | 1.2 | 16 |
| 2 | Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, . | 2.0 | 8 |
| 3 | SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , . | 0.2 | 0 |
| 4 | Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 309.e1-309.e9. | 0.6 | 2 |
| 5 | The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 844-854. | 1.9 | 13 |
| 6 | Serial comprehensive geriatric and quality of life assessments in adults age ≥50 years undergoing autologous hematopoietic cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 531-539. | 0.5 | 6 |
| 7 | A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787. | 3.2 | 14 |
| 8 | The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 132-139. | 1.2 | 8 |
| 9 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22. | 0.6 | 90 |
| 10 | Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. <i>European Journal of Haematology</i> , 2021, 107, 343-353. | 1.1 | 5 |
| 11 | Inhibition of MET Signaling with Ficlaturumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. <i>Blood Cancer Discovery</i> , 2021, 2, 434-449. | 2.6 | 7 |
| 12 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet, The</i> , 2021, 398, 491-502. | 6.3 | 315 |
| 13 | Novel Transplant and Post-Transplant Options in ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S7-S9. | 0.2 | 0 |
| 14 | JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). <i>Blood</i> , 2021, 138, 554-554. | 0.6 | 5 |
| 15 | Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States. <i>Blood</i> , 2021, 138, 4478-4478. | 0.6 | 0 |
| 16 | Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 189-196. | 2.0 | 38 |
| 17 | Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 23 |
| 18 | Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 32-33. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007. | 2.0 | 64 |
| 20 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1050-1063. | 7.7 | 288 |
| 21 | Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. <i>Blood</i> , 2019, 133, 2069-2078. | 0.6 | 47 |
| 22 | Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. <i>Blood</i> , 2019, 133, 2104-2108. | 0.6 | 63 |
| 23 | Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265. | 2.0 | 99 |
| 24 | Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1218-1224. | 2.0 | 32 |
| 25 | Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?. <i>Clinical Infectious Diseases</i> , 2018, 67, 1142-1143. | 2.9 | 57 |
| 26 | Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 897-897. | 0.6 | 7 |
| 27 | A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. <i>Blood</i> , 2018, 132, 4018-4018. | 0.6 | 1 |
| 28 | The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. <i>Blood Reviews</i> , 2017, 31, 173-183. | 2.8 | 57 |
| 29 | Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 891-893. | 0.2 | 2 |
| 30 | Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 605-610. | 1.2 | 11 |
| 31 | Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. <i>ACG Case Reports Journal</i> , 2016, 3, e162. | 0.2 | 17 |
| 32 | Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016, 128, 2899-2908. | 0.6 | 70 |
| 33 | Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1974-1982. | 2.0 | 23 |
| 34 | Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1030-1036. | 2.0 | 11 |
| 35 | Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. <i>Leukemia and Lymphoma</i> , 2016, 57, 1560-1566. | 0.6 | 11 |
| 36 | What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 543-543. | 0.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S141-S142. | 2.0 | 0 |
| 38 | Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2015, 151, 635. | 2.0 | 9 |
| 39 | ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 746-754. | 2.0 | 37 |
| 40 | Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. <i>Bone Marrow Transplantation</i> , 2015, 50, 40-44. | 1.3 | 12 |
| 41 | Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S307-S308. | 2.0 | 2 |
| 42 | A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 377-383. | 0.2 | 2 |
| 43 | Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial. <i>Blood</i> , 2015, 126, 1337-1337. | 0.6 | 0 |
| 44 | Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S65-S66. | 2.0 | 10 |
| 45 | Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2219-28. | 3.3 | 78 |
| 46 | A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S114-S115. | 2.0 | 0 |
| 47 | Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1307-1313. | 2.0 | 124 |
| 48 | Accessory splenules in autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2013, 88, 156-156. | 2.0 | 1 |
| 49 | Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S148-S149. | 2.0 | 2 |
| 50 | Cancer Vaccines and T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S97-S101. | 2.0 | 9 |
| 51 | Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1659-1665. | 3.3 | 123 |
| 52 | Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 4407-4417. | 0.6 | 118 |
| 53 | Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2012, 30, 231-235. | 0.6 | 3 |
| 54 | The road to purified hematopoietic stem cell transplants is paved with antibodies. <i>Current Opinion in Immunology</i> , 2012, 24, 640-648. | 2.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21194-21199. | 3.3 | 160 |
| 56 | Off-Label Use of Recombinant Factor VIIa. <i>Annals of Internal Medicine</i> , 2011, 155, 338. | 2.0 | 0 |
| 57 | Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications. <i>Annals of Internal Medicine</i> , 2011, 154, 529. | 2.0 | 242 |
| 58 | Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records. <i>Annals of Internal Medicine</i> , 2011, 154, 516. | 2.0 | 123 |
| 59 | Recombinant Factor VIIa: An Assessment of Evidence Regarding Its Efficacy and Safety in the Off-Label Setting. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 153-159. | 0.9 | 37 |
| 60 | High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation.. <i>Blood</i> , 2010, 116, 1290-1290. | 0.6 | 0 |
| 61 | Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 581-585. | 0.6 | 2 |
| 62 | Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms. <i>Blood</i> , 2008, 112, 482-482. | 0.6 | 0 |
| 63 | Integrated Self-Inactivating Lentiviral Vectors Produce Full-Length Genomic Transcripts Competent for Encapsidation and Integration. <i>Journal of Virology</i> , 2004, 78, 8421-8436. | 1.5 | 76 |
| 64 | Factors Influencing the Titer and Infectivity of Lentiviral Vectors. <i>Human Gene Therapy</i> , 2004, 15, 976-988. | 1.4 | 102 |
| 65 | The Moloney Murine Leukemia Virus Repressor Binding Site Represses Expression in Murine and Human Hematopoietic Stem Cells. <i>Journal of Virology</i> , 2003, 77, 9439-9450. | 1.5 | 36 |
| 66 | Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. <i>Current Opinion in Biotechnology</i> , 2002, 13, 429-436. | 3.3 | 81 |